Protocol No. V59P13E1: A Phase 3, Open-Label,Multi-Center Study to Evaluate the Persistence of Novartis MenACWY Antibody Response in Adolescents who Have Previously received either Novartis MenACWY Conjugate Vaccine or Menactra